Aminobenzenesulfonic auristatin E-d8

• UNSPSC Description:

  Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1][2].

• Target Antigen:

  Drug-Linker Conjugates for ADC; Microtubule/Tubulin

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  C[C@@H](C(N[S](=O)(C(C=C1)=CC=C1N)=O)=O)[C@H]([C@@](CCC2)([H])N2C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(C([2H])(C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])NC([C@@H](N(C)C)C(C)C)=O)=O)=O)OC

• Molecular Weight:

  761.05

• References & Citations:

  [1]Kevin HAMBLETT, et al. Anti-her2 biparatopic antibody-drug conjugates and methods of use. Patent WO2019173911A1. |[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported